Aerobic Exercise Training in Pulmonary Arterial Hypertension

Gazi University30 enrolled

Overview

Decreased exercise capacity, peripheral muscle strength and quality of life and increased dyspnea and fatigue perception is prevalent in patients with pulmonary arterial hypertension. It was demonstrated exercise training has beneficial effects in patients with pulmonary arterial hypertension. However, no study investigated the effects of upper extremity aerobic exercise training, therefore effects of upper extremity aerobic exercise training on outcomes in patients with pulmonary arterial hypertension.

Patients were diagnosed with pulmonary arterial hypertension according to the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of f the European Society of Cardiology (ESC) and European Respiratory Society (ERS). Primary outcome measurement was exercise capacity, secondary outcomes were respiratory and peripheral muscle strength, physical activity, quality of life, fatigue, dyspnea and depression.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

TRIPLE

Enrollment

Conditions

Pulmonary Arterial Hypertension

Interventions

Upper extremity aerobic exercise trainingOTHER

Training group will receive upper extremity aerobic exercise training using arm ergometer at 50-80% of maximal heart rate and breathing exercises. Training will exercise with arm ergometer 3days/week, for 6 weeks with the assistance of a physiotherapist. Training workload will be undercontrol both using target heart rate and Modified Borg dyspnea scale. Training group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks.

Alternative upper extremity exercisesOTHER

Control group will receive alternative upper extremity exercises and breathing exercises. Control group will perform alternative upper extremity exercises 3days/week, for 6 weeks and also breathing exercises 120 times/day, 7 days/week, for 6 weeks. Control group will be followed-up by telephone once a week.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinically stable * Under standard medication * Group 1 pulmonary arterial hypertension patients * Having no exacerbation or infection Exclusion Criteria: * Cognitive disorders * Orthopedic and neurological problems * Pneumonia or acute infection * Stage 4 heart failure * Having no comorbidity to avoid performing evaluation and training

Locations (1)

Gazi University

Ankara, Turkey (Türkiye)

Outcomes

Primary Outcomes

Functional exercise capacity (Oxygen consumption measurement during test)

Six minute walk test (6MWT)

Time frame: 6 weeks

Secondary Outcomes

Maximum inspiratory and expiratory muscle strength (MIP, MEP)

Mouth pressure device

Time frame: 6 weeks

Peripheral muscle strength

Hand held dynamometer

Time frame: 6 weeks

Pulmonary functions

Spirometry

Time frame: 6 week

Physical activity

Activity monitor

Time frame: 6 weeks

Dyspnea

Modified Borg and Modified Medical Research Council (MMRC) dyspnea scales

Time frame: 6 weeks

Fatigue

Fatigue Severity Scale (FSS)

Time frame: 6 weeks

Generic quality of life

Short Form (SF-36) Health Survey

Time frame: 6 weeks

Depression

Montgomery Asberg Depression Rating Scale (MADRS) (Turkish versions of all scales)

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.